Hypoxia Imaging with the novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic impact in Cervical Cancer . - 18F-FAZA
- Conditions
- Twenty-five patients with cervical carcinoma (T2Nx or TxN1) will be included in the present study. In addition to the routine pre-therapeutical staging of cervical cancer, 18FAZA PET will be performed before, during the planed radio/chemotherapy (short before brachytherapy) and 3 months after the therapy.
- Registration Number
- EUCTR2006-002251-33-AT
- Lead Sponsor
- niversity of Vienna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Female
- Target Recruitment
- 25
Inclusion Criteria
First diagnosis of histologically proven cervical cancer FIGO stage IB2 to IVA.
Treatment intention for the purpose of achieving cure
Age < 80 years
No previous standard or radical hysterectomy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Pregnancy, breast-feeding women, patients that are not able to lie motionless for one hour.
Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age > 80 years,
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method